Skip to main content

Table 3 Antibody responses to vaccine, fowlpox and CEA

From: Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer

Patient No.

Time point

Titer

  
  

Anti-Vaccinia

Anti-Fowlpox

Anti-CEA

002-001

Day 0

1600

200

NDa

 

Day 14

6400

-

<100

 

Day 28

-

-

<100

 

Day 42

-

-

<100

 

Day 70

-

3200

<100

 

Extension Phase Month 1b

-

-

<100

 

Extension Phase Month 2

-

-

<100

002-002

Day 0

1600

<100

ND

 

Day 14

3200

-

<100

 

Day 28

-

-

<100

 

Day 42

-

-

<100

 

Day 63

-

1600

<100

002–003

Day 0

400

<100

ND

 

Day 14

1600

-

<100

 

Day 28

-

<100

<100

 

Day 36

-

-

ND

002–005

Day 0

200

<100

ND

 

Day 14

800

-

<100

 

Day 28

-

-

<100

 

Day 42

-

-

100

 

Day 70

-

400

<100

002–006

Day 0

200

<100

ND

 

Day 14

800

-

<100

 

Day 28

-

-

<100

 

Day 42

-

-

3200

 

Day 70

-

800

800

 

Extension Phase Month 2

-

-

800

 

Extension Phase Month 3

-

-

400

002–007

Day 0

<100

200

ND

 

Day 14

200

-

<100

 

Day 28

-

-

<100

 

Day 42

-

-

100

 

Day 70

-

800

100

 

Extension Phase Month 2

-

-

<100

 

Extension Phase Month 3

-

-

<100

 

Extension Phase Month 4

-

-

<100

 

Extension Phase Month 5

-

-

<100

 

Extension Phase Month 6

-

-

<100

 

Extension Phase Month 7

-

-

<100

 

Extension Phase Month 8

-

-

<100

 

Extension Phase Month 9

-

-

<100

001–008

Day 0

800

<100

ND

 

Day 14

6400

-

<100

 

Day 28

-

-

<100

 

Day 42

-

3200

<100

001–009

Day 0

800

<100

ND

 

Day 14

800

-

<100

 

Day 28

-

<100

<100

001–010

Day 0

400

<100

ND

 

Day 14

1600

-

<100

 

Day 28

-

-

<100

 

Day 42

-

100

100

001–011

Day 0

1600

100

ND

 

Day 14

1600

-

<100

 

Day 28

-

-

<100

 

Day 42

-

-

<100

 

Day 70

-

800

200

 

Extension Phase Month 2

-

-

100

  1. Bolded values indicate development of antibody response, which is defined as a 2-fold increase in titer of the post-immunization sample as compared to the corresponding negative control sample. aND: not determined. Because the time 0 sample is the negative control sample for the CEA ELISA, a titer cannot be assigned to this sample. bFor this patient, the sample collected approximately 2 weeks after the day 70 vaccination was labeled "Extension Phase Month 1"; for all other patients, the sample collected one month after the day 70 vaccination was labeled "Extension Phase Month 2".
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us